Eloxx Pharmaceuticals (ELOX) news
Recent news
Eloxx Pharmaceuticals Inc: Leerink partners initiates coverage with outperform rating; target price $32
AInvest Wire · Sep 18, 2026Eloxx Pharmaceuticals - Topline data from 16-week study expected mid-2027; final readout by end of 2027
Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) is anticipated to release topline data from a 16-week clinical study of its investigational therapy mid-2027, with a final readout expected by the end of the year [1]. The study is part of the company’s ongoing efforts to advance its pipeline in the…
AInvest Wire · Sep 11, 2026Eloxx Pharmaceuticals announces first patients dosed in phase 2B exact study of exaluren in nonsense mutation Alport syndrome
AInvest Wire · Sep 11, 2026Eloxx Pharmaceuticals Q2 operating expenses USD 4.45 million
AInvest Wire · Aug 12, 2026Eloxx Pharmaceuticals Q2 net income USD -4.502 million
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) reported a net loss of $4.5 million , or $(0.39) per share, for the second quarter ended June 30, 2026. The company also recorded a net loss of $8.3 million for the six months ended on the same date. Research and development expenses for the quarter…
AInvest Wire · Aug 12, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.